You are here

Vascepa

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Fierce Pharma

Flag link:

The top 10 drugs losing U.S. exclusivity in 2021

The top 10 drugs losing U.S. exclusivity in 2021

Fierce Pharma

Flag link:

Amarin vs. the Generics: Who Will Win?

Amarin vs. the Generics: Who Will Win?

Motley Fool

Flag link:

AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts

AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts

Fierce Pharma

Flag link:

Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire

Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire

Endpoints

Flag link:

Amarin Patent Appeal Is a Coin Toss With Billions on the Line

Amarin Patent Appeal Is a Coin Toss With Billions on the Line

Yahoo/Bloomberg

Flag link:

ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment

ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment

Fierce Pharma

arterial plaque

Flag link:

Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Fierce Pharma

Flag link:

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Motley Fool

Flag link:

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

Fierce Pharma

Flag link:

FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?

FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?

Endpoints

Flag link:

Can Amarin's Stock Recover From Its 70% Implosion?

Can Amarin's Stock Recover From Its 70% Implosion?

Motley Fool

Flag link:

Are Amarin's Blockbuster Dreams Over?

Are Amarin's Blockbuster Dreams Over?

Motley Fool

Flag link:

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Fierce Pharma

Flag link:

Amarin aims for Vascepa boom with doubled sales force nearly in place

Amarin aims for Vascepa boom with doubled sales force nearly in place

Fierce Pharma

Flag link:

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

Fierce Pharma

Flag link:

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

Fierce Pharma

Flag link:

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

Fierce Pharma

clinical trials

Flag link:

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Endpoints

Flag link:

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Yahoo/Marketwatch

Flag link:

Pages